Retrophin Inc. said Thursday that it had resolved all outstanding disputes with former pharmaceutical executive and convicted stock fraudster Martin Shkreli, who founded the biopharmaceutical company in 2011.

A spokeswoman Retrophin confirmed Thursday that it had settled a lawsuit that Shkreli filed last month from prison, where he is serving a seven-year sentence for defrauding investors in two hedge funds he created. The suit, which sought at least $30 million in damages, accused Retrophin’s former CEO and two executives of “unceremoniously and illegally” ousting Shkreli for their own gain.